ライフサイエンスコーパス: propylthiouracil

1 s (thiamazole [methimazole], carbimazole, or propylthiouracil).

2 nvironmental trigger is the antithyroid drug propylthiouracil.

3 ecially following exposure to hydralazine or propylthiouracil.

4 thyroidectomy and subsequent treatment with propylthiouracil.

5 hydralazine and 3 (10%) had been exposed to propylthiouracil.

6 reaction is insensitive to inhibition by 6-n-propylthiouracil.

7 ds contained low Km D2 activity resistant to propylthiouracil (1 mM) or to inactivation by N-bromoace

8 restriction, we modeled the binding mode of propylthiouracil, a weak inhibitor of CYB5R3 (IC50 = app

9 f the mutants to the selective D1 inhibitors propylthiouracil and aurothioglucose were unaltered.

10 rminants of the sensitivity of the enzyme to propylthiouracil and aurothioglucose.

11 necrosis factor (TNF) drugs, oncology drugs, propylthiouracil and interferons.

12 Hydralazine, minocycline, propylthiouracil and levamisole-adulterated cocaine use

13 ch as low K(m) (T(4)), 1.3 nm, resistance to propylthiouracil, and a short half-life ( approximately

14 uorescence pattern (pANCA) when treated with propylthiouracil, and changed back to anti-PR3 antibodie

15 ensitivity were assessed with ratings of 6-n-propylthiouracil, and covaried from all analyses.

16 , after the induction of hypothyroidism with propylthiouracil, and in response to T(3) administration

17 d the prevalence of exposure to hydralazine, propylthiouracil, and other drugs previously implicated

18 ve been reports suggesting that hydralazine, propylthiouracil, and several other drugs may cause some

19 The patient was managed with propylthiouracil, beta-blockers and digoxin.

20 ediated bitterness of phenylthiocarbamide or propylthiouracil, but now it encompasses additional phen

21 casionally teratogenic; and the alternative--propylthiouracil--can be hepatotoxic.

22 Ca(2+) responses were unaffected by 6-n-propylthiouracil, consistent with the expression of an u

23 ts that treatment with either hydralazine or propylthiouracil is associated with ANCA-positive vascul

24 , treatment with anti-thyroid hormone drugs (propylthiouracil or methimazole) completely rescues SMRT

25 variation in bitter taste perception of 6-n-propylthiouracil (PROP) and structurally similar compoun

26 Taste blindness to the bitterness of 6-n-propylthiouracil (PROP) has been associated with increas

27 y to taste phenylthiocarbamide (PTC) and 6-n-propylthiouracil (PROP) is a polymorphic trait mediated

28 bitter taste of phenylthiocarbamide and 6-n-propylthiouracil (PROP) is a well-studied human trait.

29 tion in sensitivity to the bitterness of 6-n-propylthiouracil (PROP) is thought to play a role in the

30 HCl, caffeine, sucrose octaacetate (SOA) and propylthiouracil (PROP) solutions were examined in 1457

31 t, by sensitivity to the bitter taste of 6-n-propylthiouracil (Prop), a heritable trait.

32 s, such as phenylthiocarbamide (PTC) and 6-n-propylthiouracil (PROP), is inherited.

33 on of late, namely hydralazine, minocycline, propylthiouracil (PTU) and levamisole-adulterated cocain

34 duced in adult rats by treatment with 0.025% propylthiouracil (PTU) for 6 weeks (PTU-S) and 1 year (P

35 Propylthiouracil (PTU) is an anti-thyroid drug that repo

36 Propylthiouracil (PTU) is favored over methimazole (MMI)

37 was induced by administration of 3 or 10 ppm propylthiouracil (PTU) to pregnant and lactating dams vi

38 slow skeletal TnI (ssTnI), were treated with propylthiouracil (PTU) to revert MHC expression from adu

39 Propylthiouracil (PTU), used to treat Graves' disease, o

40 Four were intolerant of CBZ and received propylthiouracil (PTU), with good effect in 3.

41 We determined if propylthiouracil (PTU)-induced hypothyroidismin hamsters

42 rat hearts containing alpha-MHC isoform and propylthiouracil (PTU)-treated rat hearts containing bet

43 rload (PO), and (2) sustained treatment with propylthiouracil (PTU).

44 tment with the thyroxine synthesis inhibitor propylthiouracil (PTU).

45 dominantly V1 myosin) and those treated with propylthiouracil (PTU; V3 myosin).

46 tion of TH by treating Thrb(PV/PV) mice with propylthiouracil (Thrb(PV/PV)-PTU mice) and compared the

47 document cases of vasculitis occurring after propylthiouracil treatment.

48 , we validated two new potent derivatives of propylthiouracil, ZINC05626394 (IC50 = 10.81 muM) and ZI